Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will join a panel at the Maxim Group's Late Stage Innovations in Women’s Health event on March 4, 2021, at 11:00 am ET. The discussion will be moderated by Jason McCarthy, PhD, from Maxim Group. The event aims to highlight advancements in women's health innovation. Daré focuses on developing products that enhance women's health, with multiple candidates in its pipeline, including Ovaprene® and Sildenafil Cream, 3.6%.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will participate in a live panel discussion titled The Evolution of Birth Control on February 23, 2021, at 12:30 p.m. EST during the Women’s Health Innovation Series: Contraception Innovation Summit. The discussion will explore innovation challenges in birth control. Ms. Johnson will highlight Daré's commitment to women's health and the development of three innovative contraceptive candidates: Ovaprene®, DARE-LARC1, and ORB formulations. This virtual summit aims to enhance women's contraceptive experiences, featuring stakeholders from various sectors.
Daré Bioscience, a leader in women’s health, announced that CEO Sabrina Martucci Johnson will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will cover innovative developments in women's health, including Daré's unique product portfolio.
Following the event, a recording will be available on Daré's investor relations website until March 4, 2021. The company focuses on developing differentiated therapies in contraception, vaginal health, sexual health, and fertility.
Daré Bioscience, a leader in women’s health innovation, announced that its CEO, Sabrina Martucci Johnson, will join a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference from January 11-14, 2021. The chat will be available on-demand starting January 11, 2021, at 6:00 AM ET on the company's website and will remain accessible until January 25, 2021. Daré focuses on advancing innovative therapies for women's health, offering products like Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1.
Daré Bioscience has announced that its investigational treatment, DARE-BV1, has successfully met its primary and secondary endpoints in a Phase 3 trial for bacterial vaginosis, achieving significant clinical cure rates over placebo. The study involved 307 women, demonstrating a 70.2% cure rate at 21-30 days. The treatment has received Fast Track and QIDP designations from the FDA, with a New Drug Application (NDA) submission planned for the first half of 2021. These results indicate a promising new front-line option for women suffering from bacterial vaginosis.
Daré Bioscience (NASDAQ: DARE) reported its third-quarter financial results for 2020, highlighting significant advances in its product pipeline amid a challenging environment. The company is on track to complete the DARE-BVFREE pivotal study for bacterial vaginosis and anticipates FDA submission in the first half of 2021 if results are favorable. Total expenses increased, with R&D costs rising to approximately $6.2 million due to ongoing projects like DARE-BV1 and Ovaprene. Cash and equivalents stand at $5.4 million, with recent capital raised of about $4.5 million post-quarter.
Daré Bioscience (NASDAQ: DARE) will host a conference call on November 12, 2020, at 4:30 p.m. ET to discuss its financial results for Q3 2020. The event will provide insights into the company's portfolio focused on women's health, including innovative products like Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1. Investors can join via phone or webcast, with a replay available until November 19, 2020. The company's mission is to enhance treatment options in areas including contraception and male sexual health.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will present at the 2020 BIO Investor Forum, held digitally from October 13-15, 2020. Registered attendees can access the presentation on demand during the event. Following the forum, a recording will be available in the Investor Relations section of the company's website until October 29, 2020. Daré is focused on innovative women's health products, including Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1, enhancing treatment options across various areas including contraception and sexual health.
Daré Bioscience (NASDAQ: DARE) announced the receipt of approximately $0.9 million in funding from the Bill & Melinda Gates Foundation, completing a total of $19.5 million in grant support for its user-controlled long-acting reversible contraceptive (UC-LARC), DARE-LARC1. This funding will aid in advancing the preclinical development of DARE-LARC1, designed to deliver therapeutic doses without requiring medical procedures. The technology, developed by MIT researchers, aims to address the limitations of current LARCs, offering a more flexible contraceptive solution.
Daré Bioscience, focused on women’s health, announced CEO Sabrina Martucci Johnson's participation in two virtual conferences on September 14 and 15, 2020. She will join the Women’s Health Innovation Summit's expert panel for women-centric clinical research and a CEO leadership panel, with both discussions available on-demand. Additionally, Johnson will present a company update at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 4:00 PM EDT. Live webcasts and an archive will be accessible through the company's website.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
